Yes, it's tight cash flow atm. Further R&D grants get EIQ...

Yes, it's tight cash flow atm. Further R&D grants get EIQ another 2 quarters+ before needing to worry about cap raising or revenue. It's enough time to get a result from the FDA, bump the share price into the 20's, and raise $10-20m at something like 20-25c. Decent reward from current SP.

If I recall correctly, reading between the lines somewhat, the FDA requesting further info during the review period is indicative of a positive outcome at the end. Something I took away from the last video call with Prof Strange and Deon Strydom.

Big quarter ahead with Prof Strange at another conference in London with EIQ as late-breaking news. Then the big one with FDA shortly thereafter.

A comment on trading - seems some patient hands have been loading up the bids at 15-16c recently and giving the less patient an exit. A drying of supply at the 15-16c range is lining up nicely with the news ahead.